RAD50 and in situ carcinoma: Further investigation of RES and CIS co-treatment revealed a reduction in HR activity (due to decreased Rad51, Nbs-1, Mre-11 and Rad50) by RES that could explain the suppressed repair of DNA damage caused by CIS in MCF-7 cells.